Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Современные аспекты диагностики и лечения острого миелоидного лейкоза у детей

https://doi.org/10.24287/1726-1708-2015-14-3-48-54

Полный текст:

Аннотация

Острый миелоидный лейкоз (ОМЛ) у детей представлен крайне гетерогенной группой заболеваний, в связи с этим оптимизация методов лечения данной патологии является трудной задачей. В статье, представляющей собой обзор литературы, описаны современные представления о факторах прогноза, основанных на генетических изменениях в опухолевых клетках, а также существующие на сегодняшний день возможности терапии ОМЛ.

Об авторе

Ю. А. Баровская
Республиканский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики Беларусь
Россия


Список литературы

1. Петрович СВ, Алейникова ОВ, Шумихина ТП, Чуниховский СП, Федорова ЛЮ, Сахарова ОГидр. Эпидемиологические аспекты онкогематологических забо- леваний у детей в Республике Беларусь. Вопросы онкологии. 2002;48(3): 301-5

2. Faulk K, Gore L, Сooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Pediatr Drugs. 2014; 16(3):213-27

3. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K, et al. Result of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011;155(3):366-76

4. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-52

5. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170-8

6. Сooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer. 2012;118(3):761-9

7. Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jónsson OG, Lausen B, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2013;29(3):310-5

8. Creutzig U, Zimmermann M, Bourquin J, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122(1):37-43

9. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39(4, Suppl. 3):6-11

10. Гук ЛГ. Анализ мутаций в генах FLT3, KIT, MLL, NPM1 у детей с острым мие- лоидным лейкозом. Автореф. дисс. … канд. мед. наук. М., 2010

11. Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011;4:36

12. Rubnitz JE, Inaba Н. Childhood acute myeloid leukemia. Br J Haematol. 2012;159(3):259-76

13. Pui CH, Carroll W, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-65

14. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-205

15. El Rassi F, Arellano M. Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol. 2013;7:181-97

16. Paschka P, Döhner K. Сore-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematology Am Soc Hematol Educ Program. 2013;2013:209-19

17. Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119(25): 5980-8

18. Сairoli R, Beghini A, Grillo G. Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-8

19. Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-70

20. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372-9

21. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica. 2011; 96(3):384-92

22. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86

23. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009;113(26):6558-66

24. Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. J Clin Oncol. 2010;28(16): 2674-81

25. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-603

26. Liang DC, Liu HC, Yang СP, Jaing TH, Hung IJ, Yeh TC, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on muta- tions of ASXL1, TET2, IDH1, IDH2, and DNMT3. Blood. 2013;121(15):2988-95

27. Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, et al. Combi- nation of cladribine and cytarabine is effective for childhood acute myeloid leukemia: result of the St Jude AML97 trial. Leukemia. 2009;23(8):1410-6

28. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a Сhildren’s Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood. 2008;111(3):1044-53

29. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001; 15(3):348-54

30. Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-95

31. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366-76

32. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122(1):37-43

33. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56-62

34. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patient with acute myeloid leukaemia at different risk of relapse: result of the UK MRC AML 10 trial. Br J Haematol. 2002;118(2):385-400

35. Neiwerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116(13):2205-14

36. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-9

37. Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, et al. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Leuk Res. 2011;35(10):1312-20

38. Sievers EL, Lange BG, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101(9):3398-406

39. Сampana D, Coustan-Smith E. Measurements of treatment response in childhood acute leukemia. Korean J Hematol. 2012;47(4):245-54

40. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implication of FLT3 mutations in pediatric AML. Blood. 2006;108(12): 3654-61

41. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3 a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184-98

42. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-92

43. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11): 1856-62

44. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2001;117(2):3294-301

45. Levis M, Pham R, Smith BD, Small D. In vivo studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104(4):1145-50

46. Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29(24):3293-300

47. Демидова ИА. Эпигенетические нарушения при острых лейкозах. Клиническая онкогематология. 2008;1(1):16-20

48. Garcia-Manero G, Kantarijian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271-9

49. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patient with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012;30(18):2204-10

50. Попа АВ, Горохова ЕВ, Серебрякова ИН, Фечина ЛГ, Хлебникова ОП, Тупицын ННидр. Эпигенетическая терапия индукции ремиссии у детей, больных острым миелоидным лейкозом. Клиническая онкогематология. 2008;1(1):34-8

51. Moretta A, Bottino С, Mingari MС, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002;3(1):6-8

52. Miller JS. Therapeutic application: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program. 2013;2013:247-53

53. Babor F, Fischer JC, Uhrberg M. The role of KIR genes and ligands in leukemia surveillance. Front Immunol. 2013;4:27

54. Cоколова ЮВ, Бубнова ЛН, Бессмельцев СС. Строение и функции иммуно- глобулинподобных рецепторов киллерных клеток в норме и патологии. Medline.ru - Биомедицинский журнал. 2010;11(2):635-57

55. Ljunggren HG, Kärre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-44

56. Hallett WH, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol. 2004;1(1):12-21

57. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005; 105(6):2594-600

58. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433-40

59. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-7


Для цитирования:


Баровская Ю.А. Современные аспекты диагностики и лечения острого миелоидного лейкоза у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2015;14(3):48-54. https://doi.org/10.24287/1726-1708-2015-14-3-48-54

For citation:


Barovskaya Y.A. Diagnosis and treatment of acute myeloid leukemia in children: Modern aspects. Pediatric Hematology/Oncology and Immunopathology. 2015;14(3):48-54. (In Russ.) https://doi.org/10.24287/1726-1708-2015-14-3-48-54

Просмотров: 34


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)